Efbemalenograstim alfa LA is under clinical development by Evive Biotech and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II drugs for Peritoneal Cancer have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Efbemalenograstim alfa LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Efbemalenograstim alfa LA overview

Efbemalenograstim Alfa (Yilishu / Ryzneuta) is a long-acting granulocyte colony-stimulating factor. It is formulated as solution for subcutaneous route of administration. It is indicated for the prevention and treatment of neutropenia in oncology patients after receiving chemotherapy drugs.

Efbemalenograstim alfa (F-627) is under development for the treatment of epithelial ovarian cancer including fallopian tube cancer and peritoneal cancer and metastatic cervical cancer, chemotherapy-induced neutropenia in women with stage II-IV breast cancer receiving chemotherapy. The drug candidate is administered subcutaneously as a solution. It is a long acting recombinant fusion protein containing human granulocyte colony-stimulating factor (G-CSF) and human IgG2-Fc. It acts on G-CSF receptors. The drug candidate is developed based on DiKine technology. It was also under development for the treatment of Parkinson's disease.

Evive Biotech overview

Evive Biotech formerly Generon (Shanghai) is a biotechnology company that offers research and development of therapeutic biologics. The company discovers, develops and produces biomedicines. Its pipeline products comprise F-627, F-652, F-899 and ITabs. Evive Biotech’s F-627 is a recombinant fusion protein with human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. The company’s F-637 is under development, which is intended to treat inflammatory diseases with tissue injuries and immunologic disorders; and F-899, under development, which is intended to treat patients with growth deficiency and wasting diseases. Its ITabs platform all together binds to CD3 molecules on human T cells and to specific tumor antigens. Evive Biotech is headquartered in Shanghai, China.

For a complete picture of Efbemalenograstim alfa LA’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.